GlassScriptPhysician profile
Matthew S Payne
NPI 1558520676
$12,075.15
in general payments reported to CMS, 2019-2025
35 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $1,598 · 2021: $1,993 · 2022: $1,683 · 2023: $1,602 · 2024: $1,816 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,217 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,216.91 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,858.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,661.87 | 2021-2025 | |
| Pfizer INC. | $850.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $766.86 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $586.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $482.82 | 2021-2025 | Givlaari, Oxlumo |
| Janssen Pharmaceuticals, INC | $460.69 | 2019-2022 | |
| Allergan, INC. | $447.96 | 2020-2021 | |
| Lilly USA, LLC | $418.05 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $402.59 | 2019-2023 | |
| Amgen INC. | $340.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Currax Pharmaceuticals LLC | $301.17 | 2021-2024 | Contrave, Onzetra Xsail, Nexletol |
| Biohaven Pharmaceuticals, INC. | $268.20 | 2020-2021 | |
| Exact Sciences Corporation | $257.43 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $213.78 | 2023-2025 | Auvelity, Sunosi |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.